Get the Stockscreener App
12.49
0.24%
-0.03
After Hours:
12.50
0.010
+0.08%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $12.49, with a volume of 8.41M.
It is down -0.24% in the last 24 hours and down -6.58% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$12.52
Open:
$12.4
24h Volume:
8.41M
Relative Volume:
1.04
Market Cap:
$14.91B
Revenue:
$15.05B
Net Income/Loss:
$-883.30M
P/E Ratio:
8.1634
EPS:
1.53
Net Cash Flow:
$1.89B
1W Performance:
-0.32%
1M Performance:
-6.58%
6M Performance:
+19.29%
1Y Performance:
+17.28%
1-Day Range:
$12.17
$12.51
1-Week Range:
$12.07
$12.74
52-Week Range:
$9.925
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
12.49 | 14.91B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
164.28 | 74.12B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.72 | 43.95B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.17 | 41.75B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.21 | 25.17B | 16.77B | -959.00M | 1.37B | -0.85 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
US FDA restricts imports of some Viatris drugs made at India facility - Reuters
Viatris receives FDA warning letter for 11 drugs made at India plant - Seeking Alpha
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? - Insider Monkey
Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology - The Malaysian Reserve
Cenerimod shows promise in SLE trial, Viatris reports - Investing.com
Viatris announces publication of CARE study results - TipRanks
(VTRS) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Lidocaine Patches Market to See Booming Growth 2024-2031 | Endo - openPR
Viatris's SWOT analysis: generic drug maker's stock faces growth hurdles - Investing.com
Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference - The Eastern Progress Online
Epinephrine Autoinjector Market to Grow by USD 2.44 Billion (2024-2028), Driven by Rising Allergy Prevalence and AI-Powered Market TransformationTechnavio - The Malaysian Reserve
Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers - The Eastern Progress Online
Catecholamines Drugs Market: Emerging Technology and Investor - openPR
Viatris Reports Third Quarter Financial Results for 2024 - Longview News-Journal
Viatris shareholders approve stock plan amendment, reject executive compensation By Investing.com - Investing.com Canada
Viatris shareholders approve stock plan amendment, reject executive compensation - Investing.com
(VTRS) Investment Analysis - Stock Traders Daily
Viatris Elects Directors and Amends Stock Plan at Meeting - Nasdaq
Generic Pharmaceuticals Market Future Business Opportunities - openPR
Coccidioidomycosis Drugs Market to Reach US$ 634.3 Million by 2034, Expanding at a CAGR of 4.9% | Fact.MR Report - GlobeNewswire Inc.
Anti Depression Drugs Market is expected to reach US$ 22.10 - openPR
Naloxone Market Growth in Future Scope 2024-2031 | Akorn, Inc, - openPR
Viatris Says Goodbye To Another Generics Asset - Citeline
2 Generic Drug Stocks Ready to Surge in 2025 - MarketBeat
Hypopituitarism Treatment Market to Witness Huge Growth - openPR
Hypovolemic Shock Market Growth Analysis: Industry Expansion - openPR
UK CMA fines Viatris for breaching order during Theramex deal probe - World Pharmaceutical Frontiers
Viatris fined in Morocco over merger notification, sources say - MSN
Vitaris fined in Morocco over merger notification, sources say - MSN
Morocco fines Viatris 7.58 million dirhams over Mylan-Pfizer merger - MSN
UK watchdog fines Viatris $1.9 mln over rule breach in Theramex probe - Reuters.com
Viatris Fined £1.5M For Failing To Comply With CMA Order - Law360
Viatris fined £1.5M for failure to comply with CMA order - MSN
Viatris fined £1.5M for failure to comply with CMA order (NASDAQ:VTRS) - Seeking Alpha
UK watchdog fines Viatris $1.9 million over rule breach in Theramex probe - Marketscreener.com
Viatris Fined £1.5M for CMA Order Breach - Mirage News
Viatris fined £1.5m for failure to comply with CMA order - GOV.UK
Ampicillin Market to Continue Impressive Measured Growth - openPR
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Australia Passes Strict Social Media Ban for Under-16s - PYMNTS.com
Viatris fined in Morocco over merger notification, sources say By Reuters - Investing.com
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):